报价延迟最少15分钟:2025/02/23 10:09 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.35 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
64.34/74.50
|
|
企业价值
17.19B
|
| 资产负债 |
|
每股账面净值
4.39
|
| 现金流量 |
|
现金流量率
0.04
|
| 损益表 |
|
收益
279.16B
|
|
每股收益
3.85
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/02/23 10:09 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries. |